News
VTVT
19.81
-4.25%
-0.88
Weekly Report: what happened at VTVT last week (1102-1106)?
Weekly Report · 4d ago
vTv Therapeutics GAAP EPS of -$0.94 beats by $0.15
Seeking Alpha · 11/05 22:50
Press Release: vTv Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Dow Jones · 11/05 21:01
Press Release: vTv Therapeutics Reports Third -2-
Dow Jones · 11/05 21:01
*vTv Therapeutics 3Q Loss/Shr 94c >VTVT
Dow Jones · 11/05 21:01
VTv Therapeutics: Q3 Earnings Snapshot
Barchart · 11/05 15:32
Weekly Report: what happened at VTVT last week (1026-1030)?
Weekly Report · 11/02 09:01
vTv Therapeutics Announces First Patient Randomized In Phase 2a Hybrid CATT1 Study Of Cadisegliatin In Type 1 Diabetes
Benzinga · 10/27 12:08
vTv Therapeutics randomizes first participant in CATT1 pilot study
TipRanks · 10/27 12:05
Weekly Report: what happened at VTVT last week (1019-1023)?
Weekly Report · 10/26 09:01
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Integra Lifesciences (IART) and vTv Therapeutics (VTVT)
TipRanks · 10/22 10:40
Analysts’ Opinions Are Mixed on These Healthcare Stocks: vTv Therapeutics (VTVT) and RegenXBio (RGNX)
TipRanks · 10/21 16:20
vTv Therapeutics to hold a conference call
TipRanks · 10/19 21:20
Weekly Report: what happened at VTVT last week (1012-1016)?
Weekly Report · 10/19 09:01
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS), ImmunityBio (IBRX) and vTv Therapeutics (VTVT)
TipRanks · 10/15 10:40
vTv Therapeutics Price Target Maintained With a $57.00/Share by BTIG
Dow Jones · 10/14 10:17
BTIG Reiterates Buy on vTv Therapeutics, Maintains $57 Price Target
Benzinga · 10/14 10:07
Weekly Report: what happened at VTVT last week (1005-1009)?
Weekly Report · 10/12 09:01
vTv Therapeutics announces presentation at T1D clinical, research progress
TipRanks · 10/11 19:00
VTv's HPPD Receives FDA Orphan Drug Status For Sickle Cell Disease
NASDAQ · 10/08 05:22
More
Webull provides a variety of real-time VTVT stock news. You can receive the latest news about Vtv Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About VTVT
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.